NCT03082534 2026-01-28Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaUniversity of California, San DiegoPhase 2 Completed78 enrolled
NCT02586207 2025-10-07Pembrolizumab in Combination With CRT for LA-SCCHNSanford HealthPhase 1 Completed59 enrolled 9 charts